4-iodo-2,5-dimethoxyphenylisopropylamine has been researched along with Disease Models, Animal in 43 studies
4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist
2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "The use of carbamazepine has been reported to be an effective treatment for severe depression." | 7.74 | Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? ( Akiyama, K; Araki, H; Gomita, Y; Kawasaki, H; Kitagawa, K; Kitamura, Y; Sendo, T; Shibata, K; Suemaru, K, 2008) |
| "Finally, basal mRNA level of Arc was increased in the prefrontal cortex after subchronic PCP administration as revealed with in situ hybridization." | 5.39 | Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia. ( Aznar, S; Klein, AB; Knudsen, GM; Mikkelsen, JD; Ratner, C; Santini, MA, 2013) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of etifoxine was first to re-evaluate." | 3.76 | Implication of 5-HT2 receptor subtypes in the mechanism of action of the GABAergic compound etifoxine in the four-plate test in Swiss mice. ( Bourin, M; Hascoët, M, 2010) |
| " Since dietary thiamine deficiency (TD) in mice is considered as a putative model of WKS, it was used in the present study to investigate the function of serotonergic neurons in this disorder." | 3.74 | Enhanced head-twitch response to 5-HT-related agonists in thiamine-deficient mice. ( Arai, Y; Mitazaki, S; Murata, A; Nakagawasai, O; Niijima, F; Ohba, A; Tadano, T; Tan-No, K; Wakui, K, 2007) |
| "To develop a mouse model to mimic the behavioral and neurochemical changes of Tourette syndrome (TS) by 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induction and to investigate the effects of fluoxetine and haloperidol on head twitch response (HTR) induced by DOI." | 3.74 | [Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response]. ( Dai, XM; Lu, Y; Ma, HW; Yao, Y, 2007) |
| "The use of carbamazepine has been reported to be an effective treatment for severe depression." | 3.74 | Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? ( Akiyama, K; Araki, H; Gomita, Y; Kawasaki, H; Kitagawa, K; Kitamura, Y; Sendo, T; Shibata, K; Suemaru, K, 2008) |
| "Thus, mouse strains selected for a particular trait may be leveraged to generate hypothesis-driven studies aimed at clarifying the potential role played by the environment in modulating the exhibition of the symptoms of interest." | 1.40 | A behavioural test battery to investigate tic-like symptoms, stereotypies, attentional capabilities, and spontaneous locomotion in different mouse strains. ( Ceci, C; Laviola, G; Macrì, S; Proietti Onori, M, 2014) |
| "Finally, basal mRNA level of Arc was increased in the prefrontal cortex after subchronic PCP administration as revealed with in situ hybridization." | 1.39 | Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia. ( Aznar, S; Klein, AB; Knudsen, GM; Mikkelsen, JD; Ratner, C; Santini, MA, 2013) |
| "Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology." | 1.38 | Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. ( Bonhaus, DW; McFarland, K; Price, DL, 2012) |
| " The effect of chronic ACTH treatment on 5-HT(2) receptor and 5-HT(2A)-receptor mRNA levels was not altered by the chronic administration of imipramine." | 1.35 | Increased DOI-induced wet-dog shakes in adrenocorticotropic hormone-treated rats are not affected by chronic imipramine treatment: possible involvement of enhanced 5-HT(2A)-receptor expression in the frontal cortex. ( Akiyama, K; Fujitani, Y; Gomita, Y; Kanzaki, H; Kawasaki, H; Kimoto, S; Kitagawa, K; Kitamura, Y; Ouchida, M; Sendo, T; Shibata, K; Shimizu, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (44.19) | 29.6817 |
| 2010's | 23 (53.49) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Altenbach, RJ | 1 |
| Carr, TL | 1 |
| Chandran, P | 1 |
| Hsieh, GC | 1 |
| Lewis, LG | 1 |
| Manelli, AM | 1 |
| Milicic, I | 1 |
| Marsh, KC | 1 |
| Miller, TR | 1 |
| Strakhova, MI | 1 |
| Vortherms, TA | 1 |
| Wakefield, BD | 1 |
| Wetter, JM | 1 |
| Witte, DG | 1 |
| Honore, P | 1 |
| Esbenshade, TA | 1 |
| Brioni, JD | 1 |
| Cowart, MD | 1 |
| Gunia-Krzyżak, A | 1 |
| Żelaszczyk, D | 1 |
| Rapacz, A | 1 |
| Żesławska, E | 1 |
| Waszkielewicz, AM | 1 |
| Pańczyk, K | 1 |
| Słoczyńska, K | 1 |
| Pękala, E | 1 |
| Nitek, W | 1 |
| Filipek, B | 1 |
| Marona, H | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Odland, AU | 1 |
| Kristensen, JL | 1 |
| Andreasen, JT | 1 |
| Long, H | 1 |
| Wang, C | 1 |
| Ruan, J | 1 |
| Zhang, M | 1 |
| Huang, Y | 1 |
| Hongyan, L | 1 |
| Mengjiao, Z | 1 |
| Chunyan, W | 1 |
| Yaruo, H | 1 |
| Santini, MA | 1 |
| Ratner, C | 1 |
| Aznar, S | 1 |
| Klein, AB | 1 |
| Knudsen, GM | 1 |
| Mikkelsen, JD | 1 |
| Rogóż, Z | 1 |
| Wierońska, JM | 2 |
| Acher, FC | 1 |
| Sławińska, A | 1 |
| Gruca, P | 1 |
| Lasoń-Tyburkiewicz, M | 1 |
| Papp, M | 1 |
| Pilc, A | 3 |
| Lee, MY | 1 |
| Chiang, CC | 1 |
| Chiu, HY | 1 |
| Chan, MH | 1 |
| Chen, HH | 1 |
| Proietti Onori, M | 1 |
| Ceci, C | 1 |
| Laviola, G | 1 |
| Macrì, S | 1 |
| Malkova, NV | 1 |
| Gallagher, JJ | 1 |
| Yu, CZ | 1 |
| Jacobs, RE | 1 |
| Patterson, PH | 1 |
| Nau, F | 1 |
| Miller, J | 1 |
| Saravia, J | 1 |
| Ahlert, T | 1 |
| Yu, B | 1 |
| Happel, KI | 1 |
| Cormier, SA | 1 |
| Nichols, CD | 1 |
| Canal, CE | 1 |
| Felsing, DE | 1 |
| Liu, Y | 1 |
| Zhu, W | 1 |
| Wood, JT | 1 |
| Perry, CK | 1 |
| Vemula, R | 1 |
| Booth, RG | 1 |
| Pałucha-Poniewiera, A | 1 |
| Kłodzińska, A | 1 |
| Stachowicz, K | 2 |
| Tokarski, K | 1 |
| Hess, G | 1 |
| Schann, S | 1 |
| Frauli, M | 1 |
| Neuville, P | 1 |
| Wang, S | 1 |
| Zhang, QJ | 1 |
| Liu, J | 1 |
| Ali, U | 1 |
| Wu, ZH | 1 |
| Chen, L | 1 |
| Gui, ZH | 1 |
| Wang, Y | 1 |
| Hui, YP | 1 |
| Gomes, KS | 1 |
| Nunes-De-Souza, RL | 1 |
| Bourin, M | 3 |
| Hascoët, M | 3 |
| Magalhaes, AC | 1 |
| Holmes, KD | 1 |
| Dale, LB | 1 |
| Comps-Agrar, L | 1 |
| Lee, D | 1 |
| Yadav, PN | 1 |
| Drysdale, L | 1 |
| Poulter, MO | 1 |
| Roth, BL | 1 |
| Pin, JP | 1 |
| Anisman, H | 1 |
| Ferguson, SS | 1 |
| Niimi, K | 1 |
| Takahashi, E | 1 |
| Itakura, C | 1 |
| Benekareddy, M | 2 |
| Goodfellow, NM | 1 |
| Lambe, EK | 1 |
| Vaidya, VA | 2 |
| McFarland, K | 2 |
| Price, DL | 2 |
| Bonhaus, DW | 2 |
| Li, Q | 1 |
| Luo, T | 1 |
| Jiang, X | 1 |
| Wang, J | 1 |
| Acher, F | 1 |
| Lech, T | 1 |
| Nair, AR | 1 |
| Dias, BG | 1 |
| Suri, D | 1 |
| Autry, AE | 1 |
| Monteggia, LM | 1 |
| Creed, MC | 1 |
| Hamani, C | 1 |
| Bridgman, A | 1 |
| Fletcher, PJ | 1 |
| Nobrega, JN | 1 |
| Oba, A | 1 |
| Nakagawasai, O | 2 |
| Onogi, H | 1 |
| Nemoto, W | 1 |
| Yaoita, F | 1 |
| Arai, Y | 2 |
| Tan-No, K | 2 |
| Tadano, T | 2 |
| Nic Dhonnchadha, BA | 2 |
| Matuszewich, L | 1 |
| Yamamoto, BK | 1 |
| Ogasa, T | 1 |
| Ray, AD | 1 |
| Michlin, CP | 1 |
| Farkas, GA | 1 |
| Grant, BJ | 1 |
| Magalang, UJ | 1 |
| Sipe, K | 1 |
| Leventhal, L | 1 |
| Burroughs, K | 1 |
| Cosmi, S | 1 |
| Johnston, GH | 1 |
| Deecher, DC | 1 |
| Bekku, N | 1 |
| Yoshimura, H | 1 |
| Araki, H | 2 |
| Siuciak, JA | 1 |
| Chapin, DS | 1 |
| McCarthy, SA | 1 |
| Guanowsky, V | 1 |
| Brown, J | 1 |
| Chiang, P | 1 |
| Marala, R | 1 |
| Patterson, T | 1 |
| Seymour, PA | 1 |
| Swick, A | 1 |
| Iredale, PA | 1 |
| Massé, F | 1 |
| Murata, A | 1 |
| Ohba, A | 1 |
| Wakui, K | 1 |
| Mitazaki, S | 1 |
| Niijima, F | 1 |
| Okamoto, K | 1 |
| Imbe, H | 1 |
| Kimura, A | 1 |
| Donishi, T | 1 |
| Tamai, Y | 1 |
| Senba, E | 1 |
| Zhang, C | 1 |
| Marek, GJ | 1 |
| Yao, Y | 1 |
| Ma, HW | 1 |
| Lu, Y | 1 |
| Dai, XM | 1 |
| Kitamura, Y | 2 |
| Shibata, K | 2 |
| Akiyama, K | 2 |
| Kimoto, S | 1 |
| Fujitani, Y | 1 |
| Kitagawa, K | 2 |
| Kanzaki, H | 1 |
| Ouchida, M | 1 |
| Shimizu, K | 1 |
| Kawasaki, H | 2 |
| Sendo, T | 2 |
| Gomita, Y | 2 |
| Suemaru, K | 1 |
| Flaisher-Grinberg, S | 1 |
| Klavir, O | 1 |
| Joel, D | 1 |
| Masuda, Y | 1 |
| Sugiyama, T | 1 |
43 other studies available for 4-iodo-2,5-dimethoxyphenylisopropylamine and Disease Models, Animal
| Article | Year |
|---|---|
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; | 2008 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Respo | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice.
Topics: Aminopyridines; Amphetamines; Animals; Behavior, Animal; Citalopram; Compulsive Behavior; Disease Mo | 2021 |
Gastrodin attenuates neuroinflammation in DOI-induce Tourette syndrome in rats.
Topics: Amphetamines; Animals; Behavior, Animal; Benzyl Alcohols; Cytokines; Disease Models, Animal; Glucosi | 2019 |
Rhynchophylline Attenuates Neurotoxicity in Tourette Syndrome Rats.
Topics: Amphetamines; Animals; Behavior, Animal; Cell Line; Cell Survival; Corpus Striatum; Disease Models, | 2019 |
Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia.
Topics: AIDS-Related Complex; Amphetamines; Analysis of Variance; Animals; Autoradiography; Disease Models, | 2013 |
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aminobutyrates; Amphetamines; Animals; Antipsychotic Agents; | 2013 |
N-acetylcysteine modulates hallucinogenic 5-HT(2A) receptor agonist-mediated responses: behavioral, molecular, and electrophysiological studies.
Topics: Acetylcysteine; Action Potentials; Amino Acids; Amphetamines; Animals; Benzoates; Bicuculline; Disea | 2014 |
A behavioural test battery to investigate tic-like symptoms, stereotypies, attentional capabilities, and spontaneous locomotion in different mouse strains.
Topics: Amphetamine; Amphetamines; Animals; Attention; Central Nervous System Stimulants; Circadian Rhythm; | 2014 |
Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia.
Topics: Amphetamines; Animals; Behavior, Animal; Brain Mapping; Brain-Derived Neurotrophic Factor; Contrast | 2014 |
Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactiv | 2015 |
An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist that Corrects Motor Stereotypy in Mouse Models.
Topics: 2-Naphthylamine; Administration, Oral; Amphetamines; Animals; Blood-Brain Barrier; Brain; Disease Mo | 2015 |
Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Cyclopentanes; Disease M | 2008 |
In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Analysis of Variance; Animals; Anxiety; Behavi | 2009 |
Implication of 5-HT2 receptor subtypes in the mechanism of action of the GABAergic compound etifoxine in the four-plate test in Swiss mice.
Topics: Amphetamines; Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Diazepa | 2010 |
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Biotinylation; Cells, Cultured; Corticotropin-Rele | 2010 |
Hallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in senescence-accelerated mice.
Topics: Aging; Aging, Premature; Amphetamines; Animals; Behavior, Animal; CREB-Binding Protein; Disease Mode | 2010 |
Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability.
Topics: AIDS-Related Complex; Amphetamines; Analysis of Variance; Animals; Animals, Newborn; Behavior, Anima | 2010 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Anxiolytic effects of 5-HT₁A receptors and anxiogenic effects of 5-HT₂C receptors in the amygdala of mice.
Topics: Adenoviridae; Aminopyridines; Amphetamines; Amygdala; Analysis of Variance; Animals; Anti-Anxiety Ag | 2012 |
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.
Topics: Aminobutyrates; Amphetamines; Animals; Antipsychotic Agents; Benzhydryl Compounds; Dextroamphetamine | 2012 |
Induction of the plasticity-associated immediate early gene Arc by stress and hallucinogens: role of brain-derived neurotrophic factor.
Topics: Amphetamines; Analysis of Variance; Animals; Apoptosis Regulatory Proteins; Brain Infarction; Brain- | 2013 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disea | 2012 |
Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.
Topics: 5,7-Dihydroxytryptamine; Amphetamines; Analysis of Variance; Animals; Antipsychotic Agents; Autoradi | 2012 |
Chronic fluvoxamine treatment changes 5-HT(2A/2C) receptor-mediated behavior in olfactory bulbectomized mice.
Topics: Amphetamines; Animals; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Fluvoxamine; H | 2013 |
Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety.
Topics: Amphetamines; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Animal; Dose-Response Relations | 2003 |
Long-lasting effects of chronic stress on DOI-induced hyperthermia in male rats.
Topics: Amphetamines; Animals; Behavior, Animal; Chronic Disease; Disease Models, Animal; Dogs; Fever; Hallu | 2003 |
Systemic administration of serotonin 2A/2C agonist improves upper airway stability in Zucker rats.
Topics: Airway Resistance; Amphetamines; Analysis of Variance; Animals; Blood Pressure; Denervation; Diastol | 2004 |
Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction.
Topics: Amidines; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Inte | 2004 |
Factors producing a menopausal depressive-like state in mice following ovariectomy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Affect; Amphetamines; Animals; Depression; Disease Models, A | 2006 |
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
Topics: Amphetamines; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Dextro | 2007 |
Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze).
Topics: Amphetamines; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Benzodiazepines; Disease Mod | 2007 |
Enhanced head-twitch response to 5-HT-related agonists in thiamine-deficient mice.
Topics: Amphetamines; Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Toleran | 2007 |
Activation of central 5HT2A receptors reduces the craniofacial nociception of rats.
Topics: Action Potentials; Amphetamines; Animals; Behavior, Animal; Disease Models, Animal; Drug Interaction | 2007 |
AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes.
Topics: Amphetamines; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Drug Interact | 2008 |
[Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response].
Topics: Amphetamines; Animals; Disease Models, Animal; Dopamine; Fluoxetine; Haloperidol; Homovanillic Acid; | 2007 |
Increased DOI-induced wet-dog shakes in adrenocorticotropic hormone-treated rats are not affected by chronic imipramine treatment: possible involvement of enhanced 5-HT(2A)-receptor expression in the frontal cortex.
Topics: Adrenocorticotropic Hormone; Amphetamines; Animals; Antidepressive Agents, Tricyclic; Binding Sites; | 2008 |
Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors?
Topics: Adrenocorticotropic Hormone; Amphetamines; Animals; Antidepressive Agents; Carbamazepine; Depression | 2008 |
The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder.
Topics: Amphetamines; Analysis of Variance; Animals; Behavior, Animal; Compulsive Behavior; Conditioning, Op | 2008 |
The effect of globopentaosylceramide on a depression model, mouse forced swimming.
Topics: Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; | 2000 |